Drug manufacturer Eli Lilly is moving to buy Waltham-based biotech company Morphic Holding Inc. in a $3.2 billion deal. According to a statement, Lilly will pay $57 a share in cash for Morphic ...

Eli Lilly has bolstered its inflammatory bowel disease (IBD) pipeline with a $3.2 billion bid to acquire Morphic and its mid-stage oral integrin therapy MORF-057. Lilly is launching a tender offer ...

Eli Lilly’s Morphic acquisition brings an oral small ... Eli Lilly is paying $140 million for the exclusive right to buy Radionetics Oncology for the price of $1 billion. The clinical-stage ...